Tadalafil, commonly known by its brand name Cialis, is traditionally prescribed for erectile dysfunction but has gained attention in biohacking and wellness communities for potential longevity benefits. Online clinics and prominent figures in health and technology circles have begun promoting the medication as beneficial for cardiovascular health, cognitive function, and athletic performance, despite it not being formally approved for these uses.
Several observational studies conducted in recent years have documented correlations between tadalafil use and positive health outcomes. Research analyzing medical records of thousands of men taking the medication found significantly lower rates of cardiovascular death and overall mortality. Separate analysis involving over half a million patients indicated reduced dementia risk among users. Dr. Robert Kloner, chief science officer at the Huntington Medical Research Institute, characterizes these findings as consistent across the literature and calls the evidence “a very interesting signal,” though he emphasizes the need for more rigorous research.
Tadalafil belongs to a class of drugs known as PDE-5 inhibitors, which function by preventing the breakdown of signaling molecules that relax smooth muscle cells and dilate blood vessels throughout the body. Beyond erectile dysfunction, the medications are approved for treating pulmonary hypertension and enlarged prostate symptoms. Lab and animal studies suggest potential anti-inflammatory effects, and evidence from small human trials indicates possible cardiovascular benefits.
However, researchers caution that existing studies are observational and retrospective, meaning they can only demonstrate associations rather than causation. Unknown factors may influence why men seeking erectile dysfunction treatment experience better health outcomes. Additionally, the medications are less studied in women. Direct-to-consumer online clinics have increasingly marketed low-dose tadalafil for longevity purposes, with some charging approximately $70 monthly. While medical directors at these companies argue current evidence justifies offering the medication to adults over 40, some experts express concern about off-label use without more comprehensive human data, noting that absence of documented harm does not guarantee safety.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI